We have shown previously that chronic low-dose arsenic exposure induces malignant transformation of human skin keratinocyte HaCaT cells. In this study, we found that several isoforms of aldo-keto reductase 1C (AKR1C) were overexpressed in arsenic-exposed HaCaT cells. The AKR1C family of proteins are phase I drug-metabolizing enzymes involved in maintenance of steroid homeostasis, prostaglandin metabolism and metabolic activation of polycyclic aromatic hydrocarbons. To explore the oncogenic potential of AKR1C isoforms, we established mouse NIH3T3 cell lines ectopically and stably expressing human AKR1C1, AKR1C2 or AKR1C3. Our results showed that ectopic expression of human AKR1C1 and AKR1C2, but not AKR1C3, significantly enhanced foci formation. Following subcutaneous injection of these stable cell lines into nude mice, fibrosarcoma were formed from all three cell lines. However, the number and size of tumors formed by the AKR1C3-expressing cell line was fewer and smaller, respectively, than those formed by AKR1C1-and AKR1C2-expressing cells. Inhibitors of AKR1C, genistein and ursodeoxycholic acid, decreased foci formation in AKR1C1-and AKR1C2-expressing NIH3T3 cells in a dose-dependent manner, implying the association of enzymatic activity and oncogenic potential of AKR1C. The requirement of enzymatic ability for neoplastic transformation was confirmed by establishing a NIH3T3 cell line stably expressing a mutant AKR1C1 lacking enzymatic activity, which did not form foci in culture or tumors in nude mice. Our present study reveals that AKR1C enzymatic activity plays crucial roles on induction of neoplastic transformation of mouse NIH3T3 cells.
Introduction
The aldo-keto reductase 1C (AKR1C) family proteins are NAD(P)(H)-dependent oxidoreductases that catalyze the reduction of aldehydes and ketones to generate alcohol that is further conjugated by other enzymes (1) . Human AKR1C isozymes (AKR1C1-AKR1C4) are recognized as phase I drug-metabolizing enzymes (1) . They play pleiotropic roles in human physiology and pathology, such as regulation of steroid hormone activity via reduction and oxidation of ketosteroids and hydroxysteroids, which leads to subsequent activation or inactivation of downstream signaling (2) , activation of polycyclic aromatic hydrocarbons and detoxification of nicotine-derived nitrosamino-ketone (1) .
The expression of the AKR1C isozymes can be enhanced by a variety of agents, including electrophiles, polycyclic aromatic compounds and reactive oxygen species (ROS) (3) . Recent studies have further shown that expression of AKR1C isoforms is upregulated and associated with disease progression in a variety of cancers (4) (5) (6) (7) (8) (9) . However, little is known about the role of AKR1C isoforms in the malignant transformation process, except for the involvement of AKR1C3 in the development of prostate cancer via local production of active androgen in the prostate gland (10) .
Several recent studies have shown that AKR1C1 overexpression is associated with resistance to a variety of anticancer drugs, including adriamycin, daunorubicin and cisplatin (4, 11) . It has been postulated that the AKR1C1 enzyme may detoxify therapeutic agents (4, 11) or remove the reactive oxygen radicals induced by these drugs (12) . However, the mode of action of AKR1C1 on drug resistance is not clear.
In addition to medical application, arsenic widely exists in nature and is further released into the environment via industrial, agricultural and medical applications (13) and is a well-documented human carcinogen. Epidemiological evidence has shown a strong association between chronic exposure to arsenic and increased incidence of various cancers, such as lung, skin, bladder, liver and kidney cancers (14) (15) (16) . However, the carcinogenic mechanisms of arsenic at the cellular and molecular levels remain obscure. Numerous reports have shown that long-term exposure of rodent and human cell lines to low concentrations of arsenic induces a variety of biochemical and cellular changes that promote neoplastic transformation or tumor development (17) (18) (19) . We have previously investigated the effects of longterm arsenic stress on genetic and epigenetic alterations in cultured human keratinocytes (HaCaT) (20) and urothelial cells (HUC-1) (21) . These studies inferred that cellular and/or adaptive responses to sustained arsenic stress might be mediated by genetic and/or epigenetic alterations, which have been shown to potentiate neoplastic transformation (22, 23) . These studies also demonstrated that non-tumorigenic HaCaT cells become tumorigenic if subjected to sustained arsenic stress prior to injection into nude mice (20) . The established tumorigenic cell lines exhibited altered expression of keratins and chromosomal alterations (20) .
We further adopted a colorimetric complementary DNA microarray technique (24) to compare gene expression profiles between long-term arsenite-exposed HaCaT cells (A2) and untreated HaCaT cells (A0). We noticed that the expression of AKR1C1/AKR1C2 and AKR1C3 were remarkably increased in arsenite-stressed A2 cells (supplementary Figure 1 is available at Carcinogenesis Online). These findings prompted us to evaluate whether AKR1C isoforms play certain roles in neoplastic transformation. Therefore, in this study, we determined the oncogenic potential of human AKR1C isoforms by stably and ectopically expressing various AKR1C isoforms in mouse fibroblasts (NIH3T3) and examining foci formation, a characteristic of NIH3T3 cell neoplastic transformation (25) . The tumorigenicity of ectopic expression of human AKR1C isoforms in NIH3T3 cells was then confirmed using a xenograft model in nude mice.
Materials and methods

Plasmids
The human AKR1C1-AKR1C3 sequences were amplified by polymerase chain reaction (PCR) from pOTB7-AKR1C1, pDNR-LIB-AKR1C2 and pDNR-LIB-AKR1C3, respectively. The plasmids were kindly provided by the Genome Research Center, National Yang-Ming University, Taiwan. The amplified DNA fragments were inserted into pFLAG-CMV22 (Sigma, St Louis, MO). The QuickChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) was used to create Y55F, H222I and Y305F mutations in the AKR1C1 sequence. In brief, the mutants were generated using the pFLAG-CMV22-AKR1C1 template and the following primers: for Y55F, 5#-CATATTGATTCTGCTCATTTATTCAATAATGAGGAGCAGGTTGGA-3# (forward) and 5#-TCCAACCTGCTCCTCATTATTGAATAAATGAGCAGA-ATCAATATG-3# (reverse); for H222I, 5#-ATAGTGCTCTGGGATCCATC-CGAGAAGAACCATGGG-3# (forward) and 5#-CCCATGGTTCTTCTCG-GATGGATCCCAGAGCACTAT-3# (reverse) and for Y305F, 5#-GCCTAA-ACAGAAATGTGCGATTTTTGACCCTTGATATTTTTGC-3# (forward) and 5#-GCAAAAATATCAAGGGTCAAAAATCGCACATTTCTGTTTAGGC-3# (reverse) (26) . All plasmids were verified by sequencing.
Cell culture and stable transfection HaCaT cells, spontaneously immortalized human keratinocytes kindly provided by N.E.Fusenig (German Cancer Research Center, Heidelberg, Germany), were exposed to 0, 0.5 or 1 lM sodium arsenite for 20 passages and designated as A0, A1 or A2 cells, respectively, as described previously (20) . Mouse NIH3T3 cells were obtained from Dr Chung-Ming Chang (National Yang-Ming University). A0, A1, A2 and NIH3T3 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen), 1% glutamine and antibiotics (100 U/ml penicillin and 100 lg/ml streptomycin) at 37°C in a humidified atmosphere containing 10% CO 2 (20) . Transfection of plasmids carrying various human AKR1C isoforms into NIH3T3 cells was performed using the FuGene 6 transfection reagent (Roche Diagnostics, Basel, Switzerland) and followed the protocol provided by the manufacturer. At 48 h posttransfection, stable transfectants were selected by the addition of G418 (600 lg/ml, Invitrogen) to growth medium for 10 days.
Reverse transcription-PCR Total RNA was extracted using TRI reagent (Molecular Research Center, Cincinnati, OH) and reverse transcribed using an oligo(dT) primer and the AMV Reverse Transcriptase System (Roche), and the resulting complementary DNA was amplified by PCR using AKR1C isoform-specific primers. The PCR conditions were 94°C for 5 min, followed by 30 cycles of 94°C for 30 s, 57°C for 30 s and 72°C for 30 s and finally 72°C for 10 min. The PCR products were analyzed on a 2% agarose gel. GAPDH messenger RNA (mRNA) levels were analyzed in parallel as an internal control. The primers for amplification of specific AKR1C family were as following: AKR1C1, 5#-GTAAAGCTT-TAGAGGCCAC-3# (forward) and 5#-GAGGTCAACATAATCCAATTG-3# (reverse); AKR1C2, 5#-AACCAGGCCAGTGACAGAAA-3# (forward) and 5#-AGCAGCCTGTGGTTGAAGTT-3# (reverse); AKR1C3, 5'-CCAATGT-CTCTAAAGCCAGG-3# (forward) and 5#-TAGACATCAGGCAAAGCCCT-3# (reverse); AKR1C4, 5#-GACGCCACTACCAAAAGATG-3# (forward) and 5#-CTGATCCGCTGCTCATTGTA-3# (reverse) and GAPDH, 5#-TGGTAT-CGTGGAAGGACTCA-3# (forward) and 5#-AGTGGGTGTCGCTGTTGA-AG-3# (reverse).
Western blot analysis
Cells were scraped from culture dishes using a rubber policeman, lysed immediately in sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer and heated at 95°C for 10 min. Protein concentrations were determined using a protein assay dye (Bio-Rad, Munich, Germany). Equivalent amounts of sample were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. Membranes were blocked with 5% skim milk in phosphate-buffered saline containing 0.2% Tween 20 for 1 h at room temperature and then incubated with primary antibodies against AKR1C1/AKR1C2 (Cashmere Biotech, Taipei, Taiwan), FLAG (Sigma) or b-actin (Abcam, Cambridge, MA), as indicated, and followed by incubation with horseradish peroxidase-conjugated secondary antibody (Organon Teknika-Cappel, Turnhout, Belgium). Antibodybound proteins were visualized using an enhanced chemiluminescence system (Millipore, Billerica, MA) according to the manufacturer's instructions.
Cytotoxicity assay
The cytotoxicity of arsenite was determined using the sulforhodamine B (SRB) assay (27) . Briefly, HaCaT cells were plated in 96-well microplates at a density of 1000 cells per well. After addition of the indicated concentration of sodium arsenite, cells were incubated for 72 h and then fixed for 1 h with ice-cold 50% trichloroacetic acid and then stained for 30 min in a 1% acetic acid solution containing 0.4% (wt/vol) SRB. After extensive washing with distilled water, the bound SRB was extracted using 100 ll 10 mM Tris-base that had not been adjusted for pH and measured using a 96-well plate reader (SpectraMax 340PC384, Molecular Devices, Sunnyvale, CA). Survival curve data are expressed as percent absorbance relative to untreated control cells.
Foci formation assay
The foci formation assay was performed according to the procedure described by Tsuchiya et al. (28) with slight modifications. One million NIH3T3 cells were evenly plated into ten 60 mm dishes in medium containing 2% fetal bovine serum (FBS) and insulin-transferrin-selenium (Invitrogen) and incubated for 7 days followed by incubation in medium containing only 2% FBS for another 14 days. During the culture period, the medium was changed every 3 days. Cells were then fixed in methanol and stained using crystal violet solution to evaluate foci formation.
Tumorigenicity assay
Male Balb/c nude mice 4-6 weeks of age were obtained from the National Laboratory Animal Center (Taipei, Taiwan) and injected subcutaneously with 5 Â 10 5 cells in 100 ll of phosphate-buffered saline at each of two sites on either side of the back. Six animals were used per cell line and were maintained on regular food and water. Upon first appearance and weekly thereafter, tumors were measured at points of largest and smallest diameter. Animal care was approved by and followed the guidelines of the Academia Sinica Institutional Animal Care and Utilization Committee.
Enzyme activity assay
The enzyme activity of AKR1C was assayed according to the procedure described by Palackal et al. (29) with slight modifications. Logarithmically growing cells were scraped from culture dishes using a rubber policeman, lysed in 100 mM potassium phosphate buffer (pH 7.0) containing 1 mM ethylenediaminetetraacetic acid and sonicated. The cell lysates were obtained by centrifugation at 12 000 r.p.m. for 30 min. Protein concentration of clear lysates was determined using a protein assay dye. An aliquot of cell lysate was then mixed in 1 ml reaction mixture containing 1 mM 1-acenaphthenol, 2.3 mM NAD þ and 100 mM potassium phosphate buffer (pH 7.0). Enzyme reaction was monitored by the change in absorbance of pyridine nucleotide at 340 nm.
Results
Analysis of various AKR1C isoforms in HaCaT cells chronically exposed to arsenite
In previous study, we established arsenite-exposed cells using HaCaT cells treated for 20 passages with 0 lM (A0), 0.5 lM (A1) or 1 lM (A2) of sodium arsenite (20) . By aid of a colorimetric complementary DNA microarray technique (24), we noticed that the expressions of AKR1C1/AKR1C2 and AKR1C3 were remarkably increased in arsenite-stressed A2 cells as compared with unstressed control A0 cells (supplementary Figure 1 is available at Carcinogenesis Online). To confirm this finding, protein levels of AKR1C1/AKR1C2 were validated by western blot analysis. As shown in Figure 1A , AKR1C1/ AKR1C2 was highly expressed in A1 and A2 cells but was barely detectable in A0 cells ( Figure 1A ). There are four members of the human AKR1C family, and their gene sequences are very similar (30) . To detect expression of the four human AKR1C isoforms, isoform-specific primers for reverse transcription-PCR amplification of transcripts were modified from a study by Ji et al. (31) . Using these specific primers, we confirmed the enhanced expression of AKR1C1, AKR1C2 and AKR1C3 mRNA in A1 and A2 cells, respectively ( Figure 1B ), compared with A0 cells. AKR1C4, expressed exclusively in liver, was minimally expressed in A0, A1 and A2 cells but highly expressed in HepG2-positive control cells (data not shown). Together, these results indicated that sustained arsenite stress resulted in enhanced expression of AKR1C1-3 but not AKR1C4 in HaCaT cells.
Induction of AKR1C isoforms in HaCaT cells exposed transiently to arsenite In addition to observe the enhanced expression of AKR1Cs in HaCaT cells under sustained arsenite stress (20 passages), we would like to confirm the expression of AKR1C isoforms is a response to arsenite insults. To examine the effect of short-term arsenite exposure on AKR1C expression, HaCaT cells were treated with various concentrations of arsenite (0, 0.5, 1, 2, 5 and 10 lM) for 24 h, and expression of AKR1C was examined by reverse transcription-PCR and western blot analyses. As shown in Figure 2A and B, the mRNA levels of AKR1C1 to AKR1C3 were enhanced by arsenite in a dose-dependent manner. AKR1C1 mRNA was the most significantly induced by shortterm exposure to arsenite. The levels of the AKR1C1 and AKR1C2 proteins were analyzed by western blotting and were also enhanced by arsenite treatment in a dose-dependent manner ( Figure 2C ). Temporal changes in AKR1C mRNA and protein expression in response to arsenite treatment were also examined. A gradual increase in expression of AKR1C1-3 mRNAs was observed in HaCaT cells treated with 1 lM arsenite over time (4-72 h) (data not shown), whereas the protein levels of AKR1C1/AKR1C2 were remarkably enhanced after exposure of HaCaT cells to 1 lM arsenite for 24 h ( Figure 2D ).
Foci formation in human AKR1C1-and AKR1C2-expressing mouse NIH3T3 cells Since expression of AKR1C1-3 is enhanced in response to arsenite, we were interested in examining whether enhanced expression is associated with neoplastic transformation. Because foci formation in mouse NIH3T3 cells is the established assay for determining the neoplastic transformation activity of a gene product (25), we transfected mouse NIH3T3 cells with FLAG-tagged human AKR1C1, AKR1C2 or AKR1C3 expression plasmids and established stable lines by selection in medium containing G418. As shown in Figure 3A , ectopic expression of FLAG-AKR1C1, -AKR1C2 or -AKR1C3 persisted in the established cell lines after 1 month of culture. Enhanced expression of human AKR1C1, AKR1C2 or AKR1C3 in the mouse NIH3T3 cells did not affect cell proliferation in medium containing 0, 2 or 10% FBS or the colony-forming efficiency (supplementary Figure 2 is available at Carcinogenesis Online). Although expression of AKR1C isoforms has been frequently observed in drug-resistant cell lines (32), our results (SRB assay, Figure 3B) showed that NIH3T3 cells stably expressing human AKR1C1, 2 or 3 did not become more resistant to sodium arsenite. The IC 50 values for sodium arsenite in the parental NIH3T3 cells and the human AKR1C1-, AKR1C2-and AKR1C3-expressing NIH3T3 cells were 1.45 ± 0.21 lM, 0.85 ± 0.21 lM, 1.0 ± 0 lM and 0.80 ± 0.14 lM, respectively. To examine the efficiency of foci formation in NIH3T3 cells stably expressing the various isoforms of AKR1C, cells were cultured in medium containing 2% FBS for 3 weeks. As shown in Figure 3C , NIH3T3 cells stably transfected with FLAG-AKR1C1 or -AKR1C2 formed foci but those stably transfected with vector control or FLAG-AKR1C3 did not. The frequency of foci formation in AKR1C1-and AKR1C2-expressing NIH3T3 cells was 144 ± 33 and 148 ± 16 per 10 5 cells, respectively ( Figure 3D ). Subsequently, foci were subcloned, and western blot analysis verified FLAG-AKR1C1 and FLAG-AKR1C2 expression in these subcloned cell lines ( Figure 3E ).
Tumor formation by mouse NIH3T3 cells ectopically expressing human AKR1C in nude mice Because ectopic expression of some human AKR1C isoforms in NIH3T3 cells induced foci, we examined whether human AKR1C-expressing cell lines induced tumor formation in nude mice. Nude mice were subcutaneously injected with NIH3T3 cells containing stably transfected FLAG-AKR1C expression plasmids. Within 4 weeks, tumors developed at the site of the xenograft ( Figure 4A ). Among 12 injection sites, the number of tumors derived from cells transfected with vector, AKR1C1, AKR1C2 or AKR1C3 plasmids was 2, 12, 12 and 9, respectively. Larger tumors were formed by NIH3T3 cells expressing AKR1C1 (541.3 ± 77.6 mm 3 ), AKR1C2 (648.9 ± 121.1 mm 3 ) or AKR1C3 (225.5 ± 78.8 mm 3 ) compared with vector control (25.4 ± 18.3 mm 3 ; Figure 4A and B). Figure 4C presents the histology of these tumors. The morphology of all tumors was similar and was classified as fibrosarcoma. Under higher magnification, a large amount of condensed nuclei were observed in AKR1C1-, AKR1C2-or AKR1C3-induced tumors, but not in vector control ( Figure 4C, inset) , reflecting the appearance of apoptotic cells in larger tumor size of human AKR1C1-, AKR1C2-or AKR1C3-induced tumors as compared with that induced control vector. These Association of AKR1C1 and AKR1C2 enzymatic activity with oncogenic activity Because the AKR1C1 and AKR1C2 enzymes have hydroxysteroid dehydrogenase activity (31), we investigated whether the enzymatic activity of AKR1C1 and AKR1C2 is associated with oncogenic activity. First, enzyme inhibitors, such as genistein (33) and ursodeoxycholic acid (34), were added to culture medium during the foci Fig. 3 . Cytotoxicity and foci formation of mouse NIH3T3 cells stably transfected with control vector or FLAG-AKR1C1, FLAG-AKR1C2 or FLAG-AKR1C3 expression vector. (A) AKR1C isoform expression in stable transfectants was examined by western blot analysis using anti-FLAG antibody. b-Actin was analyzed as a loading control; NS, non-specific antibody binding. (B) Cytotoxicity of sodium arsenite was determined using the SRB assay after treatment of the indicated cell lines with various concentrations of arsenite for 72 h. The data represent the means ± SDs from two independent experiments. (C) The foci formation assay was performed using NIH3T3 cells stably transfected with vector control or with FLAG-AKR1C1, FLAG-AKR1C2 or FLAG-AKR1C3 expression vector. Cells were cultured for 1 week in medium containing 2% serum and insulin-transferrinselenium (Invitrogen) and then for 2 weeks in medium containing only 2% serum. Photographs of representative dishes were obtained. (D) The number of foci per 10 5 cells was determined. The data represent the means ± SDs from two independent experiments. (E) Western blot analysis with anti-FLAG antibody was performed to confirm expression of the indicated FLAG-tagged AKR1C isoform in foci derived from NIH3T3 cells stably transfected with AKR1C1 or AKR1C2 expression vector; NS, non-specific antibody binding. formation assay. Ursodeoxycholic acid (0.03-3 lM) was not cytotoxic to NIH3T3 cells but effectively inhibited foci formation of AKR1C2-expressing NIH3T3 cells ( Figure 5A ). As shown in Figure 5B , ursodeoxycholic acid at 3 lM reduced 70% of the number of foci formed as compared with untreated cells. However, ursodeoxycholic acid suppressed foci formation less effectively in AKR1C1-expressing NIH3T3 cells than in AKR1C2-expressing cells (Figure 5A and B) . Genistein also similarly suppressed foci formation in AKR1C1-and AKR1C2-expressing cell lines in a dose-dependent manner ( Figure 5C and D) .
Secondly, to confirm the requirement of AKR1C1 enzymatic activity for oncogenic transformation, we constructed three AKR1C1 mutants using site-direct mutagenesis as described by Couture et al. (26) . Accordingly, the Y55F mutant lost all enzymatic activity, the H222I mutant mainly lost 20a-hydroxysteroid dehydrogenase (HSD) activity, and the Y305F mutant remained the same as wild-type activity. Mouse NIH3T3 cells stably expressing AKR1C1 mutants were established and verified by western blot analysis ( Figure 6A ). Enzyme activity of AKR1C1 mutants in cell lysates of mouse NIH3T3 cells was monitored by NAD þ -dependent oxidation of 1-acenaphthenol. As shown in Figure 6B , the enzyme activity from cell lysate expressing Y55F mutant was limited, whereas that from H222I and Y305F mutants was similar to wild-type AKR1C1. Furthermore, NIH3T3 cells ectopically expressing wild-type AKR1C1, Y305F or H222I mutant formed foci but not those expressing Y55F mutant ( Figure  6C ). When these stable lines were subcutaneously injected into nude mice, all but the Y55F-expressing cell line induced tumors ( Figure  6D ). The average tumor size induced by cells expressing wild-type AKR1C1, Y305F or H222I was 398.8 ± 99.5, 167.4 ± 58.4 and 52.5 ± 45.4 mm 3 , respectively. The tumor size formed by H222I-expressing cells was smaller than that formed by expressing wild-type and Y305F AKR1C1, which have full enzymatic activity. These results suggested that enzymatic activity other than 20a-HSD activity is associated with the transformation activity of AKR1C1.
Discussion
Proteins of the AKR1C family have been well documented to play a pivotal role in maintaining steroid hormone homeostasis and in regulating prostaglandin metabolism (10) . In our present study, we demonstrated that the expression of AKR1C1, AKR1C2 and AKR1C3 was enhanced in response to chronic or acute sodium arsenite exposure in cultured HaCaT cells. We further showed that ectopic expression of human AKR1C1 or AKR1C2, but not AKR1C3, in mouse 3T3 cells induced foci formation in culture. However, 3T3 cells stably expressing human AKR1C1, AKR1C2 or AKR1C3 formed tumors when subcutaneously injected into nude mice. Results of experiments with inhibitors of AKR1C1 and AKR1C2 showed that enzymatic activity is probably required for the oncogenic activity of AKR1C1 and AKR1C2. The requirement for enzymatic activity in oncogenic transformation and tumor formation was confirmed by using AKR1C1 mutants with full, partial or no enzymatic activity. Our results indicated that AKR1C isoforms, ectopically expressed in mouse 3T3 cells, might have oncogenic potential.
In the present study, we confirmed that chronic exposure of human HaCaT cells to low doses of arsenite or brief exposure to acute doses of arsenite induces AKR1C1, AKR1C2 and AKR1C3 expression. Because ROS production is one of the major deleterious responses of cells to arsenite exposure and plays crucial roles in arsenic-related diseases (35) , it is probably that arsenite-induced expression of the AKR1C isoforms is associated with ROS production. However, further investigation will be required to verify this association. In general, expression of AKR1C isoforms is upregulated by monofunctional inducers, bifunctional inducers and ROS (3). Promoter analysis has revealed that electrophilic and oxidative stress may activate the expression of the AKR1C1-AKR1C3 genes (36) via consensus antioxidant response elements identified in the promoter regions. Furthermore, the antioxidant response element in the AKR1C2 promoter is regulated by the transcription factor Nrf2 (37) , which was also demonstrated to be enhanced at the transcriptional and protein levels via H 2 O 2 production in human HaCaT cells treated with arsenite (38) . As shown in supplementary Figure 3A and B (available at Carcinogenesis Online), we confirmed that Nrf2 expression was enhanced in dose-and time-dependent manners in HaCaT cells treated with arsenite. Moreover, sustained Nrf2 activation may be responsible for arsenite carcinogenesis (39). These results implicated that Neoplastic transformation by AKR1C isoforms chronic arsenite may lead to Nrf2 activation and hence continued expression of AKR1C isoforms.
In addition to Nrf2 pathway, several other pathways have been reported to participate in arsenite-induced transformation, such as p53 pathway (40), PI-3K/Akt (41) or c-Jun/AP-1 (42) pathwaymediated cyclin D1 expression. In general, adaptive responses take place when cells are under sustained environmental and/or genotoxic stress (22) . The adaptive response to genotoxic stress mainly occurs by adjustment of the levels and/or activity of the genome-protective machinery and of molecules involved in DNA repair, cell cycle checkpoints, apoptosis, metabolism and response to oxidative stress (22) that initially protect cells from genomic insults caused by genotoxic agents. However, recent evidence has shown that adaptive imbalance may be promutagenic (22) . For example, overexpression of antioxidant enzymes (manganese superoxide dismutase, catalase or glutathione peroxidase) induces genome destabilization and/or chromosomal damage in human cells (43) . Sustained genotoxic stress has been proposed to activate the mutator phenotype via epigenetic alterations and hence induce neoplastic transformation (23) . Recent studies using various toxicogenomic approaches have revealed that misdirected epigenetic alterations induced by environmental stress may lead to a variety of diseases, including cancers (44, 45) .
Foci transformation of mouse 3T3 cells has been frequently used to identify genes responsible for oncogenic transformation (46) . In the mouse 3T3 cell system, arsenite was shown to induce foci formation alone or in a two-stage transformation assay (47) . In our present study, stable expression of human AKR1C isoforms in mouse 3T3 cells did not influence cell growth rate and colony formation efficiency (supplementary Figure 2A and B is available at Carcinogenesis Online). However, ectopic expression of human AKR1C1 and AKR1C2 induced foci formation, suggesting that upregulation of these genes may lead to neoplastic transformation. The oncogenic potential of AKR1C1 and AKR1C2 was further supported by tumor formation in nude mice. Although 3T3 cells expressing AKR1C3 did not form foci, these cells formed tumors in nude mice but the tumor frequency and size was diminished compared with tumors from AKR1C1-or AKR1C2-expressing cells. Therefore, we inferred that ectopic expression of these three AKR1C isoforms probably results in oncogenic transformation of mouse 3T3 cells.
The mechanism underlying induction of neoplastic transformation by AKR1C isoforms is not completely clear. Previous studies have demonstrated that these isoforms mediate prostaglandin and androgen metabolisms to promote cell growth in prostate cancers (10) . Enhanced expression of AKR1C3 has been observed in prostate and breast cancers (8, 9) , whereas AKR1C3 expression has been shown to prevent the proliferation of human myeloid leukemia (48) . Expression of AKR1C1 and AKR1C2 is upregulated in numerous cancers, such as non-small-cell lung cancer, esophageal carcinoma, uterine cervical cancer and gastric cancer (4-7), but their expression is suppressed in breast and prostate cancers (31, 49) . These conflicting observations indicate that the AKR1C isoforms may be distinctly regulated in different tissues but also participate in different metabolic pathways.
In the present study, ursodeoxycholic acid and genistein were adopted to inhibit the foci formation in NIH3T3 cells expressing human AKR1C1 or AKR1C2, implying that the enzymatic activity is required for the neoplastic transformation. The differential inhibition on foci formation by these two inhibitors may be explained by different spectrum of substrate specificity of AKR1C1 and AKR1C2 (1). Besides, genistein has been shown to inhibit numerous kinases, such as protein tyrosine kinases and AKT (50) . Genistein may be through multiple mechanisms to suppress AKR1C1-and AKR1C2-induced foci formation. However, we confirmed the requirement of enzyme activity for foci and tumor formation by constructing various mutants of AKR1C1. These results imply that metabolites produced by enzymatic activity of AKR1C1 and AKR1C2 may participate in neoplastic transformation.
Since AKR1C isoforms catalyze the oxidation and/or reduction of a wide spectrum of substrates, their dysregulation such as overexpression may result in neoplastic transformation via different metabolic pathways. For example, numerous reports using lung cancer cells have shown that increased expression of AKR1Cs results in metabolic activation of carcinogenic polycyclic aromatic hydrocarbons to produce redox-active o-quinones, which may contribute to the generation of ROS and development of lung cancer (51) . On the other hand, Fig. 6 . Enzymatic activity of AKR1C1 is required for neoplastic transformation. (A) Western blot analysis using anti-FLAG antibody was performed to verify expression of the indicated FLAG-tagged wild-type (WT) or mutant AKR1C1 in stably transfected NIH3T3 cells. b-Actin was analyzed as a loading control; NS, non-specific antibody binding. (B) Enzyme activity of wild-type (WT) or mutant AKR1C1. Cell lysates were isolated and same amount of protein was assayed for 1-acenaphthenol oxidation. Data were presented as increased enzymatic activity as compared with parental NIH3T3 cells. The data represent the means ± SDs from three independent experiments. (C) Quantification of foci formation. NIH3T3 cells stably transfected with FLAG-tagged wild-type (WT) or mutant AKR1C1 expression plasmid were cultured as described in Figure 3C , and foci were quantified under a dissection microscope. The data represent the means ± SDs from two independent experiments. (D) Tumorigenicity of NIH3T3 cells stably transfected with wild-type (WT) or mutant AKR1C1 expression plasmid was assayed by subcutaneous injection of cells into nude mice. Tumor formation was assessed weekly. Tumor volume was determined at day 28 following injection of the indicated NIH3T3 cell line. Data are presented as dot plots, and the short black lines indicate mean tumor size. Tumor size was determined as described in Figure 4 .
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5a-dihydrotestosterone, a ligand of the androgen receptor, is inactivated by AKR1C2, and therefore, downregulation of AKR1C2 may promote prostate cancer development (52) . AKR1C3 may provide proliferative signals via estradiol, progesterone and prostaglandin F production in breast and prostate cancers (9, 10) . AKR1C1 and AKR1C2 showed stronger 3b/3a-HSD activity than AKR1C3 (1). Since H222I mutant without 20a-HSD activity is able to oxidize 1-acenaphthenol and induce foci and tumor, we infer that endogenous metabolites involved in AKR1C isoforms-induced neoplastic transformation are generated other than 20a-HSD activity of AKR1C isoforms. Therefore, it warrants our further investigation to identify the oncogenic metabolites of AKR1Cs in various tissues.
In addition to the oncogenic potential of the AKR1C genes, overexpression of AKR1C1 and AKR1C2 in ovarian, cervical, germ cell, lung and cutaneous squamous cell carcinomas was shown to be responsible for resistance to anticancer drugs (32, 53) . AKR1C2 overexpression was significantly associated with invasiveness of urinary bladder cancers among patients from areas with endemic blackfoot disease (54) in which residents had been chronically exposed to arsenic through drinking arsenic-tainted artesian well water (55) . Our recent study showed that AKR1C1 and AKR1C2 were overexpressed in HaCaT cells subjected to long-term treatment with low doses of arsenite. These results support that AKR1C expression is indeed a cellular response to arsenite-induced insults for adaptation to the detrimental environment.
In conclusion, we found that sustained arsenite exposure is associated with induced expression of the metabolic enzymes AKR1C1-3 in HaCaT cells and ectopic expression of human AKR1C1-3 in mouse 3T3 cells leads to neoplastic transformation. Besides, AKR1C isoforms were downstream molecules of Nrf2-signaling pathway that was demonstrated involved in arsenic carcinogenesis (37, 39) . Therefore, the involvement of AKR1C family and their endogenous metabolites in arsenic-mediated transformation warrant our concerns. Since specific inhibitors of the different AKR1C isoforms have been developed recently (34, 56) , future studies to determine whether these inhibitors restrict arsenite carcinogenesis may be important for development of potential cancer prevention. Supplementary Figures 1-3 can be found at http://carcin. oxfordjournals.org/ Funding Academia Sinica; National Science Council of Republic of China (NSC94-2320-B-001-036, NSC95-2320-B-001-016 and NSC96-2320-B-001-005).
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